Wednesday delivered an unexpected boost for Moderna as the biotechnology firm's stock surged more than 6%, marking a dramatic reversal from its prolonged downward trajectory. News that Pfizer had reached a framework agreement with the U.S. government regarding medication price reductions triggered widespread relief among investors. The immediate result was substantial buying activity throughout the industry, with Moderna benefiting from the sector-wide momentum. Data showed traders acquired 140,207 call options on Moderna shares, representing a 57% increase over the average daily volume. While sector developments provided immediate relief, Moderna's fundamental challenges continue to present obstacles to sustained growth.